Janux Therapeutics, Inc. Shareholders' Equity
Janux Therapeutics, Inc. (JANX) had Shareholders' Equity of $927.98 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-06
- 2026-06-30: Stockholders' Equity Attributable to Parent $927.98M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $941.53M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $956.82M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $976.55M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $927.98M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $941.53M 10-Q · filed 2026-08-06 |
| 2025-12-31 | $956.82M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $976.55M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $990.52M 10-Q · filed 2026-08-06 |
| 2025-03-31 | $1.01B 10-Q · filed 2026-08-06 |
| 2024-12-31 | $1.02B 10-Q · filed 2026-08-06 |
| 2024-09-30 | $656.10M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $657.68M 10-Q · filed 2025-11-06 |
| 2024-03-31 | $655.76M 10-Q · filed 2025-08-07 |
| 2023-12-31 | $344.35M 10-K · filed 2026-02-26 |
| 2023-09-30 | $348.95M 10-Q · filed 2024-11-06 |
| 2023-06-30 | $299.47M 10-Q · filed 2024-11-06 |
| 2023-03-31 | $311.26M 10-Q · filed 2024-08-07 |
| 2022-12-31 | $320.74M 10-K · filed 2026-02-26 |
| 2022-09-30 | $331.51M 10-Q · filed 2023-11-07 |
| 2022-06-30 | $343.81M 10-Q · filed 2023-11-07 |
| 2022-03-31 | $356.08M 10-Q · filed 2023-08-08 |
| 2021-12-31 | $366.33M 10-K · filed 2025-02-27 |
| 2021-09-30 | $376.75M 10-Q · filed 2022-11-10 |
| 2021-06-30 | $384.80M 10-Q · filed 2022-11-10 |
| 2021-03-31 | -$16.77M 10-Q · filed 2022-08-09 |
| 2020-12-31 | -$14.64M 10-K · filed 2023-03-10 |
| 2020-09-30 | -$13.04M 10-Q · filed 2021-11-09 |
| 2020-06-30 | -$11.81M 10-Q · filed 2021-11-09 |
| 2020-03-31 | -$9.35M 10-Q · filed 2021-08-10 |
| 2019-12-31 | -$7.94M 10-K · filed 2022-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |